ORG Partners’s Avadel Pharmaceuticals AVDL Stock Holding History

ORG Partners’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-188	Closed	-$2.65K	–	1182
2024 Q2	$2.65K	Buy	188 +59	+46%	+$962	﹤0.01%	1475
2024 Q1	$2.15K	Buy	+129	New	+$1.92K	﹤0.01%	395

Other funds holding AVDL

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

GJL

Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return

ORG Partners's AVDL Position: Q3 2024 in Review

ORG Partners sold out of Avadel Pharmaceuticals (AVDL) in Q3 2024, closing a stake of 188 shares — an estimated $2.65K sold.

ORG Partners first reported a position in AVDL in Q1 2024 and held it in 2 quarters. The position peaked at $2.65K in Q2 2024. 176 funds tracked by Wall St. Rank hold AVDL as of Q3 2024.

ORG Partners reported no remaining Avadel Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
ORG Partners sold 188 Avadel Pharmaceuticals shares in Q3 2024, an estimated $2.65K.
ORG Partners first reported a position in Avadel Pharmaceuticals in Q1 2024 and held it in 2 quarters.
ORG Partners's Avadel Pharmaceuticals position peaked at $2.65K in Q2 2024.
176 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q3 2024.

Based on ORG Partners's 13F filing for Q3 2024, filed 11 Oct 2024.